Dr. J. Joseph Kim has served as president and chief executive of INOVIO since 2009, leading the company’s transformation into a successful late-stage biotech focused on developing breakthrough DNA medicines that treat and protect people from diseases associated with HPV, cancer, and infectious diseases.
An immunologist by training, Dr. Kim has a deep understanding of the complexities of medical science’s greatest unsolved challenges. He is committed to improving the lives of patients, and this passion permeates the company.
Dr. Kim has published more than 100 peer-reviewed scientific papers, holds numerous patents, and sits on several scientific journal editorial boards. Most recently, he was recognized as a Young Global Leader by the World Economic Forum and a Health Innovators Fellow at The Aspen Institute. He previously co-founded VGX Pharmaceuticals, an immunotherapeutic company that he led for nine years before merging VGX with INOVIO Biomedical in 2009 to form INOVIO.
Dr. Kim earned two B.S. degrees in Chemical Engineering and Economics from the Massachusetts Institute of Technology, a Ph.D. in Immunology and an M.S. in Engineering from the University Pennsylvania, and an M.B.A. in Finance from the Wharton School.
As CFO, Mr. Kies’ primary focus is assuring INOVIO’s financial health as it reaches pipeline and commercialization goals in developing next-generation DNA medicines. As a key member of the executive leadership team, Mr. Kies is also responsible for developing and executing global financial strategy and action plans to meet the business objectives and to execute overall corporate strategy.
Prior to joining INOVIO in 2002, Mr. Kies acquired broad expertise in the functional and strategic management of biotechnology and high technology companies across the full spectrum of corporate growth, from IPO to profitability. He was previously Chief Financial Officer at Newgen Results Corporation and held positions at Cytel Corporation and Ernst & Young, LLP. He has more than 30 years of experience developing and working with Biotechnology and High-Tech companies. Mr. Kies holds a B.S. degree in Business Administration from United States International University in San Diego, CA.
As Chief Operating Officer, Dr. Shea is responsible for INOVIO’s manufacturing, commercial, business development, and alliance management operations as well as serving as a key member of the executive team and forming and implementing overall corporate strategy.
Dr. Shea was previously the CEO at Aeras, the leading not for profit organization dedicated to developing new vaccines against the global number one infectious disease killer, tuberculosis (TB). She has more than 20 years’ experience in the life science industry, working across a range of R&D and senior commercial management roles. She joined Aeras in 2014 as the Chief Operating Officer before being promoted to CEO in 2015. During her tenure Aeras delivered two major clinical breakthroughs in the development of TB vaccines. Prior to Aeras she spent eight years in a variety of senior management roles with Emergent BioSolutions, where from 2008 to 2013 she was General Manager and Vice President of The Oxford-Emergent Tuberculosis Consortium (OETC).
Dr. Shea initially trained as a molecular biologist and cell cycle geneticist and has spent much of her career dedicated to developing innovative products to prevent and treat infectious diseases. She holds twenty patents, is an author of numerous scientific publications and has served on multiple advisory boards. She received a BSc in Applied Biology from the University of Bath and a Ph.D. from the National Institute for Medical Research in the UK.
As Chief Scientific Officer, Dr. Humeau works to ensure continuous and strategic growth of INOVIO’s pipeline by introducing a constant flow of innovative concepts and cycling them from early-stage discovery and development through clinical application and patient monitoring. He provides technical and strategic leadership across multiple teams that are essential to upstream and downstream verticals of clinical development.
Dr. Humeau leads with a collaborative spirit and deeply believes in the company’s core values. He is a valuable member of the leadership team who greatly contributes to INOVIO’s culture. Prior to INOVIO, Dr. Humeau was Senior Director of Translational Research, Human Therapeutics Division for Intrexon and previously Chief Scientific Officer, Vice President of R&D at VIRxSYS Corporation. Dr. Humeau holds a Ph.D., summa cum laude, from Denis Diderot/Paris 7 University and a MS degree from Pierre & Marie Curie/Paris 6 University, Paris, France.
Dr. Bhuyan heads INOVIO’s clinical programs to treat HPV-related precancers. Dr. Bhuyan has made significant contributions to the field of vaccinology by designing, leading, and providing medical guidance for development programs at multiple companies, successfully leading many vaccine candidates from clinical trials to commercial approval at Merck and Pfizer.
Dr. Bhuyan completed his subspecialist training at the University of Pennsylvania in Infectious Diseases, where he serves as adjunct assistant professor. Dr. Bhuyan also served as medical lead in the TransCelerate BioPharma-sponsored collaborative—a large control database designed to facilitate the development of new medicines. He earned his M.D. and his Ph.D. in Immunology from the University of Texas Southwestern Medical Center, Medical Scientist Training Program.
Dr. Boyer is responsible for the Analytical Sciences Department. She leads a multidisciplinary team of talented professionals developing cutting edge analytical assays related to product characterization and clinical development supporting INOVIO’s first-in-class DNA medicines. Dr. Boyer brings her extensive expertise to product development that spans the infectious disease and immuno-oncology clinical programs. Her team supports the pipeline from Phase 1 clinical trials through filing and launch by delivering integrated analytic assays and problem solving.
Dr. Boyer worked as an Associate Research Professor at the University of Pennsylvania. Her research resulted in over 100 publications and multiple international presentations. She was responsible for some of the earliest work in defining the immune and safety profile of DNA vaccines. Dr. Boyer completed her postdoctoral studies at the University of Pennsylvania, School of Medicine and received her Ph.D. from Rutgers University.
Mr. Brandreth is responsible for all quality and compliance functions across clinical development, manufacturing and other operational areas that support INOVIO’s broad pipeline of DNA medicines. With over 30 years in life sciences including small molecules, devices and a wide variety of pivotal biotechnology products, Mr. Brandreth is a key member of the senior leadership team with a track record of moving pipeline candidates such as Rituxan®, Zevalin®, Aldurazyme® and Naglazyme® to commercialization. Mr. Brandreth will play a critical role as INOVIO ramps up its DNA medicines into late stage clinical trials.
Prior to joining INOVIO, Mr. Brandreth had a successful career transitioning start-up clinical biotech operations into successful commercial entities; he contributed to the success of several biopharmaceutical companies through his strong leadership of the quality and compliance areas. He holds an MBA from University of the Pacific and a B.A. in Biology from University of California, San Diego.
As Vice President of Business Development, Mr. Bridy is responsible for Business Development and Licensing activities at INOVIO. Mr. Bridy has over 20 years of business development, licensing, strategy, and transaction experience. Prior to joining INOVIO, Mr. Bridy was a strategic and operational advisor to over 20 life sciences operating and investment companies. Mr. Bridy also served as Head of Business Development and Licensing for Immunome, an emerging immuno-oncology company, and was a key member of the team that raised a $17.2M Series-A. At Elan Pharmaceuticals, he was responsible for out-licensing an oncology and neuroscience portfolio in their Business Development group. At GlaxoSmithKline, Mr. Bridy was responsible for diligence and valuation of oncology in-licensing and pipeline drugs in their Global Commercial Strategy group. He also served as Vice President of Strategy and Business Development at BTG plc.
Mr. Bridy has an MA in Biology and an MBA in Finance from Villanova University and a BA and BS degree in Zoology from Miami University.
Dr. Kate Broderick is an accomplished scientist and recognized vaccine expert who leads a diverse team of researchers discovering and developing DNA medicines in her role as INOVIO’s Senior Vice President of Research and Development. Working out of the company’s research labs in San Diego, she is focused on the development and enhanced delivery of a broad range of DNA medicines designed to prevent a range of often deadly infectious diseases and cancers.
Most recently, she is responsible for driving the development of a DNA vaccine for COVID-19. She also led the teams that brought the first in human Lassa fever vaccine into the clinic as well as advanced the development of a DNA vaccine for the MERS virus.
Over the course of her career, Dr. Broderick has authored and co-authored more than 60 peer-reviewed articles, and her team regularly publishes and presents their findings in leading scientific publications and at conferences worldwide. Dr. Broderick has participated by invitation at advisory meetings convened by the World Health Organization to discuss DNA vaccines and their delivery.
She is a co-inventor on multiple patents related to DNA vaccine delivery and has served as a principal investigator on grants, awards, and contracts from leading government agencies and not-for-profit organizations, including the National Institutes of Health, the U.S. Department of Defense, the Small Business Innovation Research program, and including a $56M award from the Coalition for Epidemic Preparedness Innovations (CEPI).
With a keen interest in electroporation device design in the context of transdermal delivery, Dr. Broderick has helped drive the development of novel prototypes and designs of INOVIO’s proprietary smart device CELLECTRA®, which delivers the company’s DNA medicines directly into cells in the body.
Dr. Broderick received her Ph.D. from the University of Glasgow, Scotland, and conducted post-doctoral research at the University of California, San Diego. She joined INOVIO in 2006. In 2018, Dr. Broderick was named Business Women of the Year by San Diego Business Journal.
Dr. Brown is responsible for developing and implementing INOVIO’s regulatory strategies including all submissions, compliance, promotional reviews and registrations to support INOVIO’s product development pipeline. Her technical excellence and strategic insight make Dr. Brown a key member of the leadership team as the company works to advance multiple cancer and infectious disease products through the clinical and regulatory process.
Prior to INOVIO, Dr. Brown led regulatory affairs and other functions at the Sabin Vaccine Institute in Washington, D.C. and served on the faculty in the Department of Microbiology, Immunology, and Tropical Medicine at The George Washington University. Her training and community work include supporting HIV vaccine trials at The Johns Hopkins Bloomberg School of Public Health’s Center for Immunization Research, a fellowship with the CDC’s National Centers for HIV, STD, and TB Prevention, and with the Emory Vaccine Center. Dr. Brown holds a Ph.D. in International Health with a focus in vaccine development, application, and policy from The Johns Hopkins Bloomberg School of Public Health; a Master of Public Health degree from The Rollins School of Public Health of Emory University; and a B.A. in Biology from the University of Pennsylvania.
Mr. Jordan is responsible for overall supply chain operations at INOVIO, where he drives departmental cohesiveness with purpose and vision to meet company commercialization goals. With over 25 years of experience in the medical device and environmental health and safety industries, Mr. Jordan has led many successful operational teams ranging from start-ups through large organizational IPOs. His technical and executional strengths are great assets to the company.
As a senior leader at INOVIO, Mr. Jordan is known for his dedication and meticulous approach that motivate innovative solutions and positive outcomes across all Materials departments while increasing stakeholder value and satisfaction. Mr. Jordan received an MBA in Finance from George Herbert Walker School of Business & Technology at Webster University and holds a B.S. in Business Management from San Diego State University.
Mr. Juba is responsible for ensuring the manufacturing and supply of INOVIO’s precisely designed and delivered DNA medicines and vaccine candidates for clinical use. He provides strategic and operational leadership of Supply Operations function, establishing supply processes, planning, procurement, and inventory strategies for late-stage clinical programs as well as new product launches and product line extensions.
As a chemical engineer with 20+ years of experience managing cGMP pharmaceutical and biological vaccine manufacturing for commercial and clinical products, Mr. Juba leads with extensive technical expertise to help INOVIO reach product development and commercialization goals. He previously led plasmid manufacturing at VGXI, Inc. and held several positions at Merck in bulk vaccine manufacturing operations and strategy. Mr. Juba holds a Master of Science degree in Chemical Engineering Practice and a BS degree in Chemical Engineering, both from the Massachusetts Institute of Technology.
Mr. Kemmerrer is responsible for electrical and mechanical engineering, software development and human factors for current and new device technologies used in the delivery of INOVIO’s DNA medicines. He is a well-respected and seasoned engineer who leads with an entrepreneurial spirit and brings years of experience in implementing innovative, high-impact solutions in the Biotech industry including as a developer of the Advanced Tissue Sciences human tissue mesh technology. Earlier in his career, he worked in the aerospace field building communication satellites.
Mr. Kemmerrer believes in a disciplined and focused approach to achieving strategic goals and is driven to improve patient outcomes across multiple therapeutic areas and patient populations, especially children. Mr. Kemmerrer holds a B.S. in Mechanical Engineering from University of California, Berkeley and an MBA from San Diego State University.
Ms. Lee is responsible for the operational execution of INOVIO’s pipeline and clinical compliance, providing strategic leadership across the company’s extensive DNA medicines pipeline. As a seasoned clinical research professional with more than 25 years of vaccine and drug development experience in the pharmaceutical industry and academia, Ms. Lee brings excellence to a leadership team that is keenly focused on bringing new breakthrough cancer medicines and vaccines to patients.
Ms. Lee has been with INOVIO since 2006, previously as Sr. Director of Clinical Operations and prior to that, with clinical development groups at Bristol Myers Squibb and Merck and Co. She has managed and led clinical programs in infectious disease, oncology and molecular diagnostics and has been involved in numerous INDs and NDAs. She received her MPH from Drexel University School of Public Health, MSc in Quality Assurance and Regulatory Affairs from Temple University School of Pharmacy and B.S. in Molecular Biology from Drexel University.
As head of strategic relations, Mr. Richardson brings a wealth of strategic communication expertise to bear across a wide range of external and internal efforts—including media relations, government relations, and human resources.
Prior to INOVIO, he was principal of Richardson Global PR where he assisted small public and pre-IPO pharma and biotech companies in gaining awareness and generating support in the financial and medical media, government affairs and with disease advocacy associations. He previously led major external relations efforts for Amgen and GSK. Mr. Richardson also served as a reporter and editor with Gannett News and an instructor at Temple University.
Dr. Simon is responsible for leading the Alliance and Program Management function, which supports advancement of the broad pipeline of INOVIO products. She brings over 20 years of product development and portfolio management experience to this role. She collaborates regularly with INOVIO’s Board of Directors, leadership, and product development teams to ensure delivery of INOVIO’s strategic and operational goals.
Prior to joining INOVIO, Dr. Simon spent 20 years in Project and Portfolio Management at Merck, Sharpe, and Dohme. Her professional career has focused on the discovery, development and life-cycle-management of vaccines and pharmaceutical therapies in the infectious disease therapeutic area, and management of programs in collaboration with internal as well as external partners that included industry, government, NGO, and academic partners. She served as liaison to a not-for-profit vaccine development joint venture between Merck and the Wellcome Trust, located in India.
Dr. Simon completed a post-doctoral fellowship at Merck, Sharpe and Dohme and has a Ph.D. in Cell Biology & Anatomy from the University North Carolina at Chapel Hill, an M.S. in Cell Biology & Anatomy from the University of Pittsburgh, and a B.S. in Biology from Carnegie-Mellon University.
Dr. Skolnik leads INOVIO’s immuno-oncology DNA medicines team, together with several other clinical programs. He is a key member of the leadership team overseeing global clinical assets for DNA medicines aimed to treat cancers and other diseases.
Dr. Skolnik was previously at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, and oversaw all clinical programs in oncology, infectious diseases and dermatology. He has held several leadership positions in Clinical Development and Medical Affairs for AstraZeneca and GSK, for both early and late stage compounds. Dr. Skolnik received his M.D. degree with honors from New York University and received his pediatric training at Children’s Hospital, Boston and completed his hematology/oncology training at The Children’s Hospital of Philadelphia, where he continues on staff as an Attending Physician.
As Vice President, Commercial, Mr. Twyman has responsibility for leading INOVIO’s strategic and tactical commercial effort across the HPV-targeted, infectious diseases and immuno-oncology portfolios. Mr. Twyman has more than 20 years of healthcare commercial experience across multiple product categories including vaccines, pharmaceuticals, and medical devices. Prior to joining INOVIO, Mr. Twyman held key leadership roles including VP Marketing at Novavax, VP Marketing, Pediatric Vaccines at Merck, VP/GM Vaccines at MedImmune and SVP/GM, Biosurgery at Genzyme.
Mr. Twyman earned an MBA in Finance from The Wharton School of the University of Pennsylvania and a Bachelor of Arts degree in Economics from Dickinson College.
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2020 INOVIO Pharmaceuticals. All rights reserved.